Caris Life Sciences Selects Illumina’s MiSeq® System
News Nov 09, 2012
Illumina, Inc. has announced that Caris Life Sciences has selected its MiSeq sequencing system to support Caris' evidence-based molecular profiling service.
The MiSeq system will be deployed to enable rapid, simultaneous analysis of multiple genes from formalin-fixed, paraffin-embedded (FFPE) tumor tissues using Illumina's amplicon-based assay.
Caris Life Sciences' molecular profiling service offers comprehensive tumor biomarker analyses coupled with an extensive clinical literature review, which matches potential therapies to patient-specific biomarker information.
Using a wide array of the most clinically relevant technologies available, this service continually evolves with the emerging science to help oncologists personalize care for cancer patients.
The addition of next-generation sequencing to Caris' molecular profiling service represents the next step in the natural evolution of this cutting-edge offering.
"We are pleased to be the selected sequencing platform for Caris Life Sciences, an unmatched leader in tumor profiling, whose molecular profiling service has been ordered for more than 40,000 patients to date," said Matt Posard, Senior Vice President and General Manager of Illumina's Translational and Consumer Genomics business.
Posard continued, "This collaboration is an excellent example of applying next-generation sequencing with the goal of improving patient outcomes."
Caris Life Sciences is one of the few entities to offer next-generation sequencing commercially in their CLIA-accredited laboratory, and will replace its current sequencing technology with Illumina's MiSeq system.
The addition of next-generation sequencing via the MiSeq complements the variety of highly integrated technology platforms already employed by Caris, including immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and polymerase chain reaction (PCR).
Caris' molecular profiling service uses these cutting-edge technologies to comprehensively interrogate the entire cancer biological process - including DNA, RNA, and protein analysis.
"Caris leverages the most clinically relevant technologies and biomarkers to help physicians individualize care. When we choose to add a new technology to our portfolio, we are committed to selecting a best-in-class platform and partner, as evidenced by our selection of Illumina," said Tom Spalding, Senior Vice President, Group Head Oncology and Chief Marketing Officer at Caris Life Sciences.
Spalding continued, "After a thorough evaluation of top NGS platforms, Illumina's data quality, simple workflow, and commitment to a collaborative approach were key to our decision to work with them."
CRISPR Used to Prevent Development of Angiogenesis of the RetinaNews
Powerful new technology may lead to novel therapies to prevent vision loss, blindness in those with diseases of the retina.READ MORE
Could This Be a "Silver Bullet" for Preventing and Treating Colon Cancer?News
A team of scientists targeted the gene CtBP with a drug known as HIPP (2-hydroxy-imino phenylpyruvic acid) and were able to reduce the development of pre-cancerous polyps by half.READ MORE
FDA Grants Full Approval to Blinatumomab for Acute Lymphoblastic LeukemiaNews
TheFDA has changed its accelerated approval of blinatumomab (Blincyto®) for some patients with acute lymphoblastic leukemia to a full approval and expanded the approved indications for its use.READ MORE
Comments | 0 ADD COMMENT
11th International Conference on Cancer Stem Cells
Jun 11 - Jun 13, 2018